Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Gilead Allows China/Indian Pharmas to Make Generic Version of Novel HIV Drug

publication date: Jul 29, 2014
Gilead Sciences will allow China and Indian drugmakers to start developing generic formulations of a promising novel HIV/HBV drug, even though the drug’s Phase III tests are still underway. The drug, tenofovir alafenamide (TAF), is a prodrug of the well-known antiretroviral HIV treatment Viread (tenofovir), which is also a Gilead product. China/Indian generic pharmas will be able to market TAF in 112 developing countries – countries that are home to more than 90% of the world’s HIV patients. More details....

Stock Symbol: (NSDQ: GILD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital